These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34302375)

  • 1. Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.
    Jiang H; Jiang Y; Ma H; Zeng H; Lv J
    Clin Cardiol; 2021 Sep; 44(9):1208-1215. PubMed ID: 34302375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.
    Bai Y; Deng H; Shantsila A; Lip GY
    Stroke; 2017 Apr; 48(4):970-976. PubMed ID: 28213573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study.
    Ellis MH; Neuman T; Bitterman H; Dotan SG; Hammerman A; Battat E; Eikelboom JW; Ginsberg JS; Hirsh J
    Eur J Intern Med; 2016 Sep; 33():55-9. PubMed ID: 27296588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis.
    Hua Y; Sun JY; Su Y; Qu Q; Wang HY; Sun W; Kong XQ
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):51-61. PubMed ID: 32514866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.
    Qazi JZ; Schnitzer ME; Côté R; Martel MJ; Dorais M; Perreault S
    PLoS One; 2021; 16(3):e0246691. PubMed ID: 33657116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Proietti M; Romanazzi I; Romiti GF; Farcomeni A; Lip GYH
    Stroke; 2018 Jan; 49(1):98-106. PubMed ID: 29167388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
    Sherwood MW; Nessel CC; Hellkamp AS; Mahaffey KW; Piccini JP; Suh EY; Becker RC; Singer DE; Halperin JL; Hankey GJ; Berkowitz SD; Fox KAA; Patel MR
    J Am Coll Cardiol; 2015 Dec; 66(21):2271-2281. PubMed ID: 26610874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.